It’s one step backward in order to take two steps forward at Zentalis Pharmaceuticals Inc. In a restructuring to help fund the second part of its potentially registration-enabling Denali study, ...

Zentalis Pharmaceuticals said it would cut 40% of its workforce as part of a restructuring to support the late-stage development of its cancer-drug azenosertib. The clinical-stage ...

Zentalis Pharmaceuticals LLC shares tumbled to a 52-week low, touching down at $1.76, as the biopharmaceutical company grapples with a challenging market environment. According to InvestingPro ...

Zentalis Pharmaceuticals announced a restructuring to extend its cash runway into late 2027, following a planned 40% workforce reduction, in preparation for the potentially registration-enabling ...

FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers The FDA has lifted the partial clinical hold on Zentalis Pharmaceuticals ...

O n Wednesday, Jefferies analyst Akash Tewari adjusted the price target for Zentalis Pharmaceuticals (NASDAQ:ZNTL), bringing it down to $2.50 from the previous figure of $6.00, while reiterating a ...

SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class ...

SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...